评估在澳大利亚实施20肺炎球菌结合疫苗用于儿童免疫的实施情况
Valda Anne Struwig1, An Ta2, Amit Vilas Thorat1
1Pfizer Australia, Level 15/18, 151 Clarence St, Sydney, NSW 2000, Australia.
Vaccine
|November 20, 2025
概括
在澳大利亚实施20肺炎球菌合疫苗 (PCV20).
科学领域:
- 公共卫生 公共卫生
- 疫苗学 疫苗学 疫苗学
- 卫生经济学 卫生经济学
背景情况:
- 澳大利亚国家免疫计划 (NIP) 目前使用的是13价值肺炎球菌联合疫苗 (PCV13).
- 新的疫苗,15-valent (PCV15) 和20-valent (PCV20) 肺炎球菌联合疫苗,可用,但没有由NIP资助.
- 需要进行成本效益分析,以将PCV20与现有和替代疫苗进行比较.
研究的目的:
- 将PCV20与PCV13和PCV15在澳大利亚儿科NIP中实施的公共卫生和经济影响进行比较.
- 评估PCV20作为目前肺炎球菌疫苗接种策略的潜在替代品.
主要方法:
- 付款人视角的成本效益分析,使用10年多队列模型.
- 包括疫苗对接种和未接种疫苗的人群的直接和间接影响.
- 利用澳大利亚特有的流行病学,成本和公用事业数据;从现有数据中推导出疫苗的有效性.
主要成果:
- 预计PCV20的实施将在10年内,与PCV13和PCV15相比,预防显著更多的肺炎球菌病例和死亡.
- 对于PCV20来说,与PCV13和PCV15相比,PCV20与大幅度的质量调整寿命年 (QALY) 收益和总成本节省有关.
- 概率灵敏度分析表明PCV20是高比例代中占主导地位的策略.
结论:
- 据估计,将PCV20纳入澳大利亚儿科NIP是一个占主导地位的战略.
- 与PCV13和PCV15相比,PCV20的采用预计将带来显著的健康益处和成本节省.
- 这项分析支持将PCV20纳入国家免疫计划,以改善公共卫生结果和经济效率.
相关概念视频
01:29Drug Dosing: Infants and Children
235
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
235
01:51Vaccinations
51.2K
Overview
51.2K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
196
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
01:22Development of Immunocompetence
774
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
774
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247